41. Fumeron F, Betoulle D, Nicaud V, Evans A, Kee F, Ruidavets JB, et al. Serotonin transporter gene polymorphism and myocardial infarction: Etude CasTemoins de l’Infarctus du Myocarde (ECTIM). Circulation 2002; 105: 2943-5.
42. Téllez Vargas J, Estefan Chehab R. Depresión y enfermedad cardiovascular. Cuadernos Psiquiatría de Enlace. Bogotá. 2003;(19): 8-11.
43. Lesperance F, Frasure-Smith N, Talajic M, Bourassa MG. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation. 2002;105:1049-53.
44. Lane D, Carroll D, Ring C, Beevers DG, Lip GY. Mortality and quality of life 12 months after myocardial infarction: effects of depression and anxiety. Psychosom Med. 2001;63:221-30.
45. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardio vascular disease. Epidemiology, biology and treatment. Arch Gen Psychiatry. 1998;55:580-59.
46. Kleiger RE, Miller JP , Bigger JT Jr. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol. 1987;59:256-62.
47. Maes M, Basmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine. 1997;9:853-8.
48. Kop WJ, Gottdiener JS, Tangen CM, Fried LP , McBurnie MA, Walston J, et al. inflammation and coagulation factors in persons > 65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am J Cardiol. 2002;89:419-24.
49. Broadley AJ, Korszun A, Jones CJ, Frenneaux MP . Arterial endothelial function is impaired in treated depression. Heart. 2002;88:521-4.
50. Zuckerman M, Curtis PH. Relationships among anxiety, depression, hostility, and autonomic variables. J Nerv Ment Dis. 1968;146:481-7.
51. Van Ravenswaaij-Arts CMA, Koller LAA, Hopman JC, Stoelinga GB, van Geijn HP . et al. Heart rate variability. Ann Int Med. 1993;118(6):436-47.
52. Froese AP , Cassem NH, Hackett TP , Silverberg EL. Galvanic skin potential as a predictor of mental status, anxiety, depression and denial in acute coronary patients. J Psychosom Res. 1975;19:1-9.
53. Keating MT. The long QT syndrome: a review of recent molecular genetic and physiologic discoveries. Medicine. 1996 Jan;(1):15.
54. Sullivan M, LaCroix AZ, Speretus JA,vHecht J. Five-year prospective study ofvthe effects of anxiety and depression onvsymptoms and function in patients with coronary heart disease, Am J Cardiol. 2000;86:1135-8.
55. Dickens CM, McGowan L, Percival C, Tomenson B, Cotter A, et al. Contribution of depression and anxiety to impaired health-related quality of life following first myocardial infarction. British Journal of Psychiatry 2006;189: 367-72.
56. Anil Gehi, MD; Donald Haas, MD, MPH; Sharon Pipkin, MPH; Mary A. Whooley. Depression and Medication Adherence in Outpatients With Coronary Heart Disease .Arch Intern Med. 2005;165:2508-2513.
57. John SR, Edward H, Frederick AM, Eric DP, Philip JM, Joseph FT, et al. ACC, Strongest Predictors of Short-Term Declines in Health Status in Patients With Heart Failure. Journal of the American College of Cardiology. 2003;42:215-22.
58. Appels AD, Frits BA, Van Der PG, Erdman R, Assman M, et al. Effects of Treating Exhaustion in Angioplasty Patients on New Coronary Events: Results of the Randomized Exhaustion Intervention Trial (EXIT). Psychosomatic Medicine 2005; 67:217–223.
59. Susan M. Czajkowski. Effects of Treating Depression and Low Perceived Social Support on Clinical Events After Myocardial Infarction: The Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003;289(23):3106-3116.
60. Garcia VE, Del Villar SV, García y García EL. La depresión tras el infarto agudo de miocardio. AN. MED. INTERNA (Madrid) 2007;24( 7) 346-351.
61. De Jonge P, Spijkerman TA, Van den Brink RHS, Ormel J. Depression after myocardial infarction is a risk factor for declining health related quality of life and increased disability and cardiac complaints at 12 months. Heart 2006;92;32-39.
62. Guck TP, Kavan MG, Elsasser GN, Pharm D, Barone EJ. Assessment and Treatment of Depression Following Myocardial Infarction. Am Fam Physician 2001;64:641-8,651-2.
63. Moser DK, Dracup K. Role of Spousal Anxiety and Depression in Patients’ Psychosocial Recovery After a Cardiac Event. Psychosomatic Medicine 2004;66:527–532
64. Ziegelstein RC. Depression in Patients Recovering From a Myocardial Infarction. JAMA. 2001;286:1621-1627
65. Luutonen S, Holm H, Salminen JK, Risla A, Salokangas RKR. Inadequate treatment of depression after myocardial infarction. Acta Psychiatr Scand 2002: 106: 434-4
66. Lespérance F. Frasure N. Depression and coronary artery disease: time to move from observation to trials. JAMC 2003; 168 (5): 570-71. Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry 1987; 44: 273-5.
67. Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG. Cardiovascular effects of bupropion in depressed patients withheart disease. Am J Psychiatry 1991; 148: 512-6.
68. Walley T, Pirmohamed M, Proudlove C, Maxwell D. Interaction of metoprolol and fluoxetine. Lancet 1993; 10: 341: 967-8.
69. Guck TP, Kavan MG, Elsasser GN, Barone EJ. Assessment and treatment of depression following myocardial infarctionAm Fam Physician.2001; 15: 64: 641-8. Review.
70. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT Jr, Pollock BG, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998; 28:279: 287-91.
71. Ellison JM, Milofsky JE, Ely E. Fluoxetine-induced bradycardia and syncope in two patients. J Clin Psychiatry 1991; 52: 139.
72. Song F, Freemantle N, Sheldon TA, et al. Selective Serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. Br Med J 1993; 306: 683-7.
73. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine in depressed patients with heart disease. Am J Psichiatry 1998; 155: 660-5.
74. Sauer WH, Berlin J, Kimmel S. Selective Serotonin Reuptake Inhibitors and Myocardial Infarction. Circulation 2001; 104: 1894-8.
75. Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000; 68: 435-42.
76. Rasmussen A, Hindberg I, Mellerup E. Does sertraline induced platelet dysfunction protect stroke patients against cardiovascular comorbidity?. Int.J Neuropsychopharmacol 2000; 3 (Supl. 1).
77. Pakala R, Willerson JT, Benedict CR. Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 1997; 7: 96: 2280-6.
78. Vikenes K, Farstad M, Nordrehaug JE. Serotonin is associated with coronary artery disease and cardiac events Circulation 1999; 3: 100:483-9.
79. Ashton JH, Benedict CR, Fitzgerald C, Raheja S, Taylor A, Campbell WB, et al. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation 1986; 73: 572-8).
80. Pakala R, Willerson JT, Benedict CR. Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 1997; 7: 96: 2280-6.